MAH Regimen In Treatment Of Refractory And Relapsed Acute Myeloid Leukemia

Objective: To evaluate the efficacy and safety of MAH regimen (Mitoxantrone + Ara-C + Homoharringtonine)in treatment of refractory and relapsed acute myeloid leukemia.Methods:37 patients with refractory or relapsed acute myeloid leukemia (15 refractory AML patients, 22 relapsed AML patients) were treated with the MAH regimen(Mitoxantrone 10mg qd,iv.gtt,for 2～3 days;Ara-C 100mg bid ,iv.gtt,for 5～7 days; Homoharringtonine 4mg qd iv.gtt,for 5～7 days).Results:The rate of complete remission and partial remission were 40.5%(15/37) and 2.7% (1/37), respectively.The overall response rate was 43.2%.The median follow-up time was 97 days(range,18 to 487 days).The median relapse-free survival(RFS) was 147 days(range,4 to 341 days). The most common observed side effect of the regimen were infection and hemorrhage because of myelosuppression.Conclusion:MAH regimen can be employed in treatment of the refractory or relapsed patients who were not responded to other regimen. It is effective and is good tolerant.It could provide some refractory patients the chance to receive hematopoietic stem cell transplantation.